| (P09) Combined Use of Radiosurgery With Concurrent PD-1/PD-L1 Inhibition For Metastatic Brain Lesions of NSCLC G Azzam, W Park, E Mellon, A Markoe, N Elsayyad, G Lopes, ... International Journal of Radiation Oncology, Biology, Physics 101 (2), E24, 2018 | 5 | 2018 |
| 115 Comprehensive spatial, transcriptomic, and genomic analysis of immunogenic biliary tract cancer W Park, F Keane, HS Ozkan, A Richards, V Rudneva, D Khalil, K Soares, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| 1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer F Keane, W Park, A Varghese, F Balogun, K Yu, I El Dika, D Khalil, ... Annals of Oncology 33, S1140, 2022 | | 2022 |
| 143 Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for NoneSmall-Cell Lung Cancer W Park, G Lopes, J Pacheco, PA Bunn, A Winther-Larsen, EBF Ebert, ... | | |
| 388 Preliminary results from KEYNOTE-A36, a study of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab or chemotherapy in specified advanced solid tumors J Bendell, W Messersmith, D Rasco, A Wang-Gillam, W Park, L Zhou, ... Journal for Immunotherapy of Cancer 8 (Suppl 3), 2020 | 1 | 2020 |
| 508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition D Bortone, A Monette, N Tschernia, A Cogdill, Y Najjar, RF Sweis, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
| A comparative analysis of locoregional therapy (hyperthermic intraperitoneal chemotherapy [HIPEC]) and systemic chemotherapy (CT) following cytoreductive surgery in patients … TS Bekaii-Saab, LK Martin, GD Vallabhaneni, W Park, CA Staley, ... Journal of Clinical Oncology 30 (15_suppl), e14169-e14169, 2012 | | 2012 |
| A dual‐targeting antibody against EGFR‐VEGF for lung and head and neck cancer treatment H Zhang, S Yun, TD Batuwangala, M Steward, SD Holmes, L Pan, ... International journal of cancer 131 (4), 956-969, 2012 | 45 | 2012 |
| A Loss of Function Genetic Screen Identifies Determinants of Sensitivity to PARP Inhibitor ABT-888 in Pancreatic Cancer W Park, BG Pantazides, BF El-Rayes, JW Shelton, DS Yu, JC Landry International Journal of Radiation Oncology, Biology, Physics 84 (3), S325, 2012 | | 2012 |
| A Phase 1/2 Study of GB1275, a First-in-Class CD11b Modulator, as Monotherapy and With an Anti-PD-1 Antibody in Specified Advanced Solid Tumors or With Chemotherapy in … DW Rasco, JC Bendell, A Wang-Gillam, W Park, EM O’Reilly, L Zhou, ... | | |
| A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic … J Bendell, D Rasco, W Park, L Zhou, A Galkin, D Slee, L Carter, D Nickle, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 7, 2019 | | 2019 |
| A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer. R Tuli, F Keane, JD Schoenfeld, C O'Connor, C White, JF Chou, ... Journal of Clinical Oncology 41 (16_suppl), 4164-4164, 2023 | 1 | 2023 |
| A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in … DW Rasco, JC Bendell, A Wang-Gillam, W Park, EM O'Reilly, L Zhou, ... Journal of Clinical Oncology 38 (15_suppl), 3085-3085, 2020 | 7 | 2020 |
| A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC). F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ... Journal of Clinical Oncology 41 (4_suppl), 725-725, 2023 | 1 | 2023 |
| A phase II trial of axitinib plus pembrolizumab for patients with advanced alveolar soft part sarcoma (ASPS) and other soft tissue sarcomas (STS). BA Wilky, MM Trucco, D Kolonias, E Wieder, T Subhawong, A Rosenberg, ... Journal of clinical oncology 36 (15_suppl), 11547-11547, 2018 | 13 | 2018 |
| A Review of Pancreatic Cancer—Reply W Park, A Chawla, EM O’Reilly JAMA 326 (23), 2436-2437, 2021 | 4 | 2021 |
| A single cell landscape of malignant pancreas cancer ascites S Umeda, ER Karnoub, E Ziv, J Wu, C Cruz, W Park, F Balogun, ... Cancer Research 83 (7_Supplement), 1241-1241, 2023 | | 2023 |
| A synthetic lethal screen identifies genetic determinants for gemcitabine sensitivity in pancreatic cancer JC Landry, BG Pantazides, W Park, JW Shelton, SK Maithel, B El-Rayes, ... Cancer Research 72 (8_Supplement), 3119-3119, 2012 | | 2012 |
| Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC) E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ... Cancer Research 84 (2_Supplement), B042-B042, 2024 | | 2024 |
| Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ... Cancer Research 84 (2_Supplement), B045-B045, 2024 | | 2024 |
Eileen M. O'ReillyMemorial Sloan Kettering Cancer Center在 mskcc.org 的电子邮件经过验证
